Univariable and multivariable Mendelian randomization study

identified the key role of gut microbiota in immunotherapeutic

1

32

3 toxicity 4 Baike Liu^{1,2,5}, Zheran Liu^{3,5}, Tianxiang Jiang^{1,2,5}, Xiangshuai Gu⁴, Xiaonan Yin^{1,2}, 5 Zhaolun Cai^{1,2}, Xiaoqiao Zou^{1,2}, Lei Dai^{4*}, Bo Zhang^{1,2*} 6 7 ¹ Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 8 Sichuan, 610041, the People's Republic of China. 9 ² Gastric Cancer Center, West China Hospital, Sichuan University. Chengdu, Sichuan, 10 610041, the People's Republic of China. 11 ³ Department of Biotherapy and National Clinical Research Center for Geriatrics, 12 Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, the 13 People's Republic of China. 14 ⁴ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 15 Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 16 Sichuan, 610041, the People's Republic of China. 17 ⁵ These authors contributed equally: Baike Liu, Zheran Liu, Tianxiang Jiang. 18 *e-mail: zhangbo scu@scu.edu.cn, daileisklb2012@163.com 19 20 21 Running title: Causal associations between gut microbiota and irAEs 22 23 24 25 26 27 28 29 30 31

33

34

35 36

37

38

39

40

41 42

43

44

45 46

47 48

49

50

51

52

5354

55 56

57

58

59 60

6162

6364

65

66

67

68

Abstract: Background: In cancer patients receiving immune checkpoint inhibitors (ICIs), there is emerging evidence suggesting a correlation between gut microbiota and immune-related adverse events (irAEs). However, the exact roles of gut microbiota and the causal associations are yet to be clarified. Methods: To investigate this, we first conducted a univariable bi-directional two-sample Mendelian randomization (MR) analysis. Instrumental variables (IVs) for gut microbiota were retrieved from the MiBioGen consortium (18,340 participants). GWAS summary data for irAEs were gathered from an ICIs-treated cohort with 1,751 cancer patients. Various MR analysis methods, including Inverse variance weighted (IVW), MR PRESSO, maximum likelihood (ML), weighted median, weighted mode, and cML-MA-BIC were used. Furthermore, multivariable MR (MVMR) analysis was performed to account for possible influencing instrumental variables. Results: Our analysis identified fourteen gut bacterial taxa that were causally associated with irAEs. Notably, Lachnospiraceae was strongly associated with an increased risk of both high-grade and all-grade irAEs, even after accounting for the effect of BMI in the MVMR analysis. Akkermansia, Verrucomicrobiaceae, and Anaerostipes were found to exert protective roles in high-grade irAEs. However, Ruminiclostridium6, Coprococcus3, Collinsella, and Eubacterium (fissicatena group) associated with a higher risk of developing high-grade irAEs. RuminococcaceaeUCG004, and DefluviitaleaceaeUCG011 were protective against all-grade irAEs, whereas Porphyromonadaceae, Roseburia, Eubacterium (brachy group), and *Peptococcus* were associated with an increased risk of all-grade irAEs. Conclusion: Our analysis highlights a strong causal association between Lachnospiraceae and irAEs, along with some other gut microbial taxa. These findings provide potential modifiable targets for managing irAEs and warrant further investigation. Key words: Gut microbiota, Immunotherapy toxicity, Immune-related adverse effects, irAEs, Lachnospiraceae, Akkermansia, Ruminiclostridium6, Mendelian randomization study, multivariable Mendelian randomization study, MVMR

Introduction

Applications of immune checkpoint inhibitors (ICIs), especially those targeting CTLA-4 and PD-1/PD-L1, have revolutionized the treatment of various aggressive cancers (1). By blocking inhibitory signaling pathways and reinvigorating the natural anti-tumor immune response, these inhibitors have significantly prolonged the lives of numerous cancer patients (2–5). However, due to the inhibition of the systemic brake of immune activation, ICIs can cause off-target effects resulting in immune-mediated toxicities to organs and non-malignant tissues. This newly emerging registry of iatrogenic effects, known as immune-related adverse events (irAEs), usually resemble autoimmune disorders, such as colitis, dermatitis, and thyroiditis (6). Although the majority of irAEs manifest in a mild manner, still, up to 55% of patients develop serious irAEs in combined therapy (anti-CTLA-4 and anti-PD-1) (7). Notably, serious irAEs pose significant risks to patients' well-being and may result in morbidity and mortality, not only due to the adverse event itself but also due to the need to suspend or terminate ICIs therapy and the potential impairment of the ICIs-induced immune response while using immunosuppressants (e.g. corticosteroids) (8–10). Therefore, effective management of irAEs is critical to optimize the safety and efficacy of ICIs therapy.

The precise mechanisms underlying irAEs are not fully understood, but emerging evidence indicates that the gut microbiota, a complex and dynamic system of microorganisms colonizing the intestinal tract, may play a crucial role in the regulation of irAEs. Simpson et al. found a reduced alpha-diversity of intestinal microbiota in patients who developed severe irAEs (11). Furthermore, antibiotics commonly prescribed prophylactically to hospitalized patients have been shown to increase the risk of ICIs therapy-related irAEs that are not limited to the gastrointestinal tract (12–14). The gut microbiota closely interacts with the host immune system and has been implicated in the regulation of various autoimmune and inflammatory disorders (15,16). However, consensus on the core microbial drivers or protective microbes of irAEs is still lacking, due to inconsistent findings reported in previous studies (11,17–19). The discrepancies among previous studies may be attributed to limited sample sizes and susceptibility to confounding factors such as age, diet, and medication usage in observational designs (11,20).

Mendelian randomization (MR), initially described by Katan in 1986 (21), is a novel method for inferring causal associations between modifiable risk factors and health outcomes using genetic variations as instrumental variables (IVs) (22). MR effectively addresses the limitations of confounding and measurement errors that often exist in observational studies, as the direction of causation is from the genetic polymorphism to the trait of interest, not vice versa (23). Therefore, we aim to utilize

MR, an increasingly popular method in drug discovery and epidemiology (24,25), to investigate the potential association between the gut microbiota and irAEs, providing further evidence for the management of irAEs by manipulating human gut microbiota.

2. Methods

Study design and data source

An overview of the study design was illustrated in **Figure 1.** In general, we first performed univariable bi-directional two-sample MR analysis, which utilizes single nucleotide polymorphisms (SNPs) from summary-level data as proxies for the risk factor under investigation. Then, several sensitivity analyses and multivariable MR analysis (MVMR) was conducted to further increase the robustness of our study. To ensure the validity of the MR results, three assumptions needed to be satisfied, as illustrated in **Figure S1** (22):

- (1) **Relevance assumption:** The genetic variants should demonstrate a strong association with the exposure;
- (2) **Independence assumption:** The genetic variants should not be associated with any confounders that could affect the relationship between the exposure and outcome;
- (3) **Exclusion restriction assumption:** The genetic variants should not have an independent effect on the outcome aside from their impact through the exposure.

This study is based on publicly available GWAS summary statistics and ethical approvals were acquired by the original studies.

Gut microbiota: Genetic variations associated with the composition of gut microbiota were derived from the most comprehensive genome-wide meta-analysis conducted to date by the MiBioGen consortium (26). This study included a total of 18,340 individuals from 24 cohorts worldwide, mainly of European descent (n = 13,266). Fecal DNA was extracted, and targeted sequencing of variable regions in the bacterial 16S rRNA gene (V4, V3-V4, and V1-V2 regions) was performed to profile the gut bacterial composition. To account for sequencing depth differences across cohorts, all cohorts were rarefied to 10,000 reads per sample. Taxonomic classification was performed using direct taxonomic binning method (26). Following quality control, imputation, and post-imputation filtering procedures, gut bacterial taxa observed in over 10% of samples were included in the microbiota quantitative trait loci (mbQTL) mapping (26). This allowed us to identify host genetic variants associated with the relative abundance of bacterial taxa. Further details on microbial data processing can be found in the original study. Genus-level and family-level taxa were included in our analysis, resulting in a total of 131 genus-level and 35

family-level taxa.

145146

147

148149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164165

166

167

168

169170

171172

173

174

175176

177178

179

180

181

182

irAEs: Summary-level data of irAEs was obtained from a recent GWAS conducted in the Dana-Farber Cancer Institute (DFCI) cohort (27). The study included 1,751 cancer patients of European ancestry who underwent ICIs treatments between 2013 and 2020. The majority of patients (approximately 90%) received PD-1/PD-L1 inhibitors, while the remaining 10% received combined immunotherapy (CTLA4 and PD-1/PD-L1 inhibitors). Among the 1,751 cancer patients, 259 cases that experienced high-grade irAEs (grade 3 to 5 events) were manually curated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v.5 guidelines. Additionally, algorithm-based autoimmune-like electronic health records were used to identify 339 patients who experienced any grade irAEs (referred to as all-grade irAEs). Most of these cases were grade 2 or higher events (27). The tumor tissue of these patients was sequenced using the targeted OncoPanel sequencing platform. After quality control steps, germline SNPs were imputed by utilizing ultra-low-coverage off-target reads. Then, the GWAS was conducted in the DFCI cohort to investigate the association of all variants with the time from the start of ICIs treatment to the occurrence of the two phenotypes of irAEs. For more detailed information, please refer to the original publication (27).

Selection of instrumental variables

Several steps were followed in the selection of iVs. Firstly, for the gut microbiome, we selected SNPs associated with bacterial taxa with a p-value less than 1×10^{-5} for further analysis (28,29). Secondly, potential SNPs were clumped for independence in the TwoSampleMR package in R software. We used the European 1000 Genomes Project Phase 3 reference panel and set the linkage-disequilibrium threshold (r²) at 0.001 within a 10 Mb window size. Thirdly, we extracted SNPs from the outcome statistics and performed a harmonization procedure. SNPs that were not available in the outcome GWAS data were replaced with proxy SNPs ($r^2 > 0.8$), and palindromic SNPs were removed for further MR analysis. Furthermore, F statistics of selected iVs, which indicate instrument strength, was calculated as [Beta/SE]². Typically, F statistics > 10 suggest enough iVs strength to avoid weak instrument bias (30). Finally, All SNPs with positive results were re-examined using PhenoScanner package (version 1.0) in R software to investigate the presence of potential confounders. Bacterial taxa with less than 3 valid SNPs and unknown origin were excluded from the analysis to mitigate potential bias. Consequently, we included a total of 104 genus-level and 28 family-level bacterial taxa (n = 132) for further MR analysis.

Statistical analysis

183

184

185

186 187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216217

218

219

220

In this study, we employed several MR analysis methods to explore the potential causal relationship between gut microbiota and irAEs. The methods used included IVW, MR PRESSO, ML, weighted median, weighted mode, and a constrained maximum likelihood and model averaging based method (cML-MA-BIC). IVW and MR PRESSO were used in the primary analysis. In general, IVW provides maximum statistical power when all instruments are valid (31), while MR PRESSO identifies and removes genetic variants that deviate significantly from the variant-specific causal estimates of other variants, thereby increasing statistical power and addressing potential outliers (32). The ML method resembles the IVW approach which assumes the absence of both heterogeneity and horizontal pleiotropy. If these assumptions hold true, the ML method yields unbiased results with smaller standard errors compared to the IVW approach (33). Considering the potential existence of IV pleiotropy, we also performed pleiotropy-robust methods including weighted median, weighted mode, and cML-MA-BIC in the sensitivity analysis. These methods relax the instrumental variable assumptions. Weighted median were introduced when the exclusion restriction assumption was violated (uncorrelated pleiotropy), which typically assume fewer than 50% of genetic variants are invalid (34). The weighted-mode method clusters genetic variants based on their similarity in causal effect and estimates the overall causal effect based on the cluster with the most number of iVs (35). The cML-MA-BIC method is a novel approach developed for MR analysis, specifically addressing the issue of invalid iVs exhibiting both uncorrelated and correlated pleiotropy (violation of the independence assumption) (36). By being robust to such violations, cML-MA-BIC improves the accuracy of MR analysis, reduces Type I error, and increases statistical power (36).

Next, heterogeneity and directional pleiotropy were assessed using Cochra''s Q statistics and MR Egger intercept. Leave-one-out (LOO) analysis was conducted to identify possible reliance on a specific variant, which involved excluding one SNP at a time for all valid SNPs in the IVW analysis. Additionally, reverse MR analysis between irAEs and the identified significant gut bacterial taxa was performed. Moreover, MVMR analysis, which could help us better understand the intricate interplay between the risk factors was further conducted (37). We considered a Bonferroni-corrected p-value of $3.89 \times 10^{-4} \, (0.05/132)$ as the significance threshold for gut microbiota. Two-tailed p-value < 0.05 was considered suggestive of significance. All analyses were conducted using R packages "TwoSampleMR" (version 0.5.6), "MRPRESSO" (version 1.0), and "MRcML" (version 0.0.0.9) in R software (version 4.2.2).

3. Results

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242243

244

245

246

247

248

249250

251

252

253

254255

256257

258

3.1 Genetic instruments and primary MR analysis

A total of 870 single nucleotide polymorphisms (SNPs) were selected as instrumental variables (iVs) for the 132 gut bacterial taxa (Table S1). The F statistics for each SNP ranged from 16.91 to 36.57, with a median value of 21.66. Using the IVW and MR-PRESSO methods, eight gut bacterial taxa associated with high-grade irAEs were identified with p-values < 0.05. These taxa include *Lachnospiraceae*, Verrucomicrobiaceae, Ruminiclostridium6, Coprococcus3, Anaerostipes, Akkermansia, Collinsella, and Eubacterium (fissicatena group). For all-grade irAEs, seven gut bacterial taxa, including Lachnospiraceae, Porphyromonadaceae, Roseburia, RuminococcaceaeUCG004, DefluviitaleaceaeUCG011, Eubacterium (brachy group), and Peptococcus, were identified. Given previous studies suggest that pre-existing autoimmune conditions such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis may predispose individuals to irAEs susceptibility (38,39). We further examined the SNPs associated with the significant bacterial taxa using PhenoScanner. Only one SNP (rs11597285) for the Collinsella genus was found to be associated with allergic disease (e.g. allergic rhinitis and eczema) (refer to **Table S9**). However, the results of *Collinsella* remained uninfluenced after removing rs11597285 in the LOO analysis (described below). The complete results of the primary MR analysis can be found in **Table S2** and **Table S3**.

3.2 Main MR results and sensitivity analysis for high-grade irAEs

As shown in **Figure 2,** the IVW estimate suggested the abundance of *Lachnospiraceae* family was associated with a shortened time to high-grade irAEs (Beta = -1.22, 95% CI: -1.99 to -0.44, p = 2.17×10^{-3}), indicating *Lachnospiraceae* serves as a risk factor for the development of high-grade irAEs. The deleterious effect remained significant in pleiotropy-robust cML-MA-BIC estimation (Beta = -1.24, 95% CI: -2.45 to -0.02, p = 4.62×10^{-2}). Surprisingly, *Ruminiclostridium6* genus was significantly associated with an increased risk of high-grade irAEs in all MR approaches, including IVW (Beta = -2.11, 95% CI: -2.98 to -1.23, p = 2.47×10^{-6}), cML-MA-BIC (Beta = -2.17, 95% CI: -3.49 to -0.86, p = 1.19×10^{-3}), Weighted median (Beta = -2.43, 95% CI: -4.05 to -0.81, p = 3.29×10^{-3}), and other methods. In addition, the IVW estimate indicated a protective effect of the *Akkermansia* genus on high-grade irAEs (Beta = 1.27, 95% CI: 0.28 to 2.25, p = 0.01), and this finding was confirmed by the IVW estimate of its paternal taxon *Verrucomicrobiaceae* (Beta = 1.27, 95% CI: 0.29 to 2.25, p = 0.01). The IVW estimate of *Anaerostipes* genus also indicated a suggestive protective effect against high-grade irAEs (Beta = 2.1, 95% CI:

0.85 to 3.35, p = 1.02 × 10⁻³), as well as cML-MA-BIC (Beta = 2.17, 95% CI: 0.57 to 3.77, p = 7.88 × 10⁻³). Moreover, significant effects of the *Coprococcus3* (Beta = -2.04, 95% CI: -2.7 to -1.39, p = 8.93 × 10⁻¹⁰), *Collinsella* (Beta = -1.12, 95% CI: -1.7 to -0.53, p = 1.7 × 10⁻⁴), and *Eubacterium* (*fissicatena group*) genus (Beta = -0.73, 95% CI: -1.01 to -0.46, p = 1.93 × 10⁻⁷) were all revealed by IVW estimate, indicating an increased risk of high-grade irAEs. Scatter plots reflecting the effect size of iVs on both bacterial taxa and high-grade irAEs are shown in **Figure 4**.

In the subsequent analysis of heterogeneity and horizontal pleiotropy, Cochra's

In the subsequent analysis of heterogeneity and horizontal pleiotropy, Cochra's Q statistics revealed no significant heterogeneity (p-value> 0.05) among the iVs for the gut bacterial taxa in high-grade irAEs analysis (see **Table 1**). No significant evidence for directional horizontal pleiotropy was found in the MR-Egger regression intercept analysis and MR PRESSO global test (**Table 1 and Table S4**). Additionally, the LOO analysis identified no predominant SNP that influenced the results (**Figure 6**). We further performed reverse MR analysis and demonstrated no reverse causation exists between high-grade irAEs and the abundance of gut bacterial taxa (**Table S6**).

3.3 Main MR results and sensitivity analysis for all-grade irAEs

267

268

269

270

271

272

273

274275

297

276 **Figure 3** reveals the association between bacterial taxa and all-grade irAEs. It is 277 noteworthy that the deleterious impact of the Lachnospiraceae family was also detected in all-grade irAEs, as revealed by IVW (Beta = -2.05, 95% CI: -3.27 to -0.82, 278 $p = 1.06 \times 10^{-3}$), cML-MA-BIC (Beta = -2.21, 95% CI: -3.32 to -1.1, $p = 9.16 \times 10^{-5}$), 279 and Weighted median estimates (Beta = -1.72, 95% CI: -3.2 to -0.24, $p = 2.25 \times 10^{-2}$). 280 The IVW estimate of Roseburia genus also showed an increased risk of all-grade 281 irAEs (Beta = -2.07, 95% CI: -3.21 to -0.93, p = 3.76×10^{-4}). Consistent results were 282 observed in ML (Beta = -2.07, 95% CI: -3.67 to -0.47, p = 1.14×10^{-2}) and 283 cML-MA-BIC (Beta = -2.08, 95% CI: -3.71 to -0.45, p = 1.23×10^{-2}) estimates. On 284 the contrary, *Ruminococcaceae UCG004* (Beta = 1.07, 95% CI: 0.43 to 1.72, p = 1.05 285 \times 10⁻³) and *DefluviitaleaceaeUCG011* (Beta = 0.82, 95% CI: 0.38 to 1.25, p = 2.15 \times 286 10⁻⁴) were identified to decrease the risk of all-grade irAEs according to the IVW 287 288 approach. Subsequently, the results for Ruminococcaceae UCG 004 were consistent with the cML-MA-BIC (Beta = 1.1, 95% CI: 0.04 to 2.15, $p = 4.12 \times 10^{-2}$) and ML 289 method (Beta = 1.09, 95% CI: 0.04 to 2.14, $p = 4.16 \times 10^{-2}$). Moreover, the IVW 290 estimates suggested that *Porphyromonadaceae* (Beta = -1.11, 95% CI: -1.83 to -0.39, 291 $p = 2.46 \times 10^{-3}$), Eubacterium (brachy group) (Beta = -0.71, 95% CI: -1.14 to -0.27, p 292 $= 1.38 \times 10^{-3}$), and *Peptococcus* (Beta = -0.71, 95% CI: -1.24 to -0.18, p = 8.82×10^{-3}) 293 may increase the risk of all-grade irAEs. Scatter plots reflecting the effect size of each 294 295 IV on both bacterial taxa and all-grade irAEs are shown in **Figure 5**. 296 Similarly, Cochran's Q statistics indicated an absence of notable heterogeneity in

the iVs of gut bacterial taxa (refer to Table 1). In addition, the results from the

MR-Egger regression intercept analysis and the MR PRESSO global test demonstrated no significant evidence of directional horizontal pleiotropy (**Table 1** and **Table S4**). Next, no significant single SNP was identified in the LOO analysis that influenced the results (**Figure 7**). Overall, these results provide evidence for the association between specific gut bacterial taxa and the development of high-grade and all-grade irAEs, and highlight the potential role of the gut microbiota in irAEs.

3.4 Multivariable MR analysis

Given the strong correlation between body mass index (BMI) and gut microbiota (40,41), we incorporated BMI and weight-associated anthropometric traits, as well as several lifestyle risk factors associated with irAEs (42), into the univariable MR analysis. Detailed GWAS datasets information of these anthropometric traits and lifestyle risk factors can be found in **Table S10**. The univariable MR analysis suggested a correlation between BMI and an increased risk of all-grade irAEs (**Table 2**). Thus, we performed subsequent MVMR analysis by including BMI as an additional exposure alongside previously identified gut microbial taxa (**Table S11**). Notably, after accounting for the effect of BMI in the MVMR analysis, *Lachnospiraceae* still remained significantly associated with the risk of developing all-grade irAEs (Beta = -1.07, 95% CI: -1.96 to -0.18, p = 0.02), and high-grade irAEs (Beta = -0.91, 95% CI: -1.84 to 0.01, p = 0.05) with a marginal p value (**Table 3**).

4. Discussion

In this study, univariable bi-directional MR and MVMR analyses were conducted to infer the causal association between gut microbiota and irAEs. We identified fourteen gut bacterial taxa that were causally associated with high-grade and all-grade irAEs. Surprisingly, *Lachnospiraceae* strong associated with an increased risk of both irAEs phenotypes, even after accounting for the effect of BMI in the MVMR analysis. Additionally, we found robust evidence indicating that *Ruminiclostridium6* predisposes ICIs receivers to developing high-grade irAEs. *Coprococcus3*, *Collinsella*, and *Eubacterium* (*fissicatena group*) were also associated with an increased risk of high-grade irAEs, while *Akkermansia*, *Verrucomicrobiaceae*, and *Anaerostipes* exhibited protective roles in high-grade irAEs. For all-grade irAEs, *Porphyromonadaceae*, *Roseburia*, *Eubacterium* (*brachy group*), and *Peptococcus* were associated with an elevated risk, while *RuminococcaceaeUCG004* and *DefluviitaleaceaeUCG011* were associated with a reduced risk.

Several observational studies have demonstrated associations between gut microbiota and irAEs (11,17–19,43,44). *Lachnospiraceae* species (such as

335

336

337

338

339

340341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365 366

367

368

369

370

371

372

373

Coprococcus and Roseburia), which are obligately anaerobic, variably spore-forming bacteria, were found to correlate with increased risk of various types of irAEs (17,18,45). In a more recent study, two species of the *Lachnospiraceae* family were specifically enriched in irAEs that occur in endocrine organs (46). Consistent with these findings, we also identified the *Lachnospiraceae* family, and its two genera (i.e., Coprococcus3 and Roseburia) associated with an increased risk of irAEs. Importantly, the harmful influence of the Lachnospiraceae family was observed in high-grade irAEs and all-grade irAEs, even after adjusting the effect of BMI, which provides further validity and robustness to our study. Ruminiclostridium6 has been less studied in irAEs, but some studies have observed its accumulation in a mouse model of DSS-induced colitis. While treated with phloretin (a dihydrochalcone flavonoid) or sodium butyrate (one of the short chain fatty acids [SCFAs]), both of which alleviates DSS-induced colitis, the abundance of Ruminiclostridium6 was reduced (47,48). In Ruminiclostridium genus has also been associated addition, the autoimmune-related diseases, such as the experimental multiple sclerosis model and Alzheimer's disease (49,50). Based on our strong association of *Ruminiclostridium6* with increased risk of high-grade irAEs, it is suggested that Ruminiclostridium6 may play a pivotal role in the development of autoimmune conditions and could be a potential target for relieving irAEs symptoms, although more evidence is needed.

Akkermansia muciniphila, an anaerobic gram-negative species that belongs to Akkermansia genus, and Verrucomicrobiaceae family, has gained much attention in immunotherapy due to their association with a favorable response in ICIs therapy (51–53). Akkermansia muciniphila has also been shown to exhibit a protective role in ICIs-associated colitis (54). Mechanically, Wang et al. demonstrated that Akkermansia muciniphila and its purified membrane protein mitigated colitis by regulating macrophages and CD8+ T cells in the colon tissue (55). Our study further supported the protective role of Akkermansia in high-grade irAEs. Ruminococcaceae, a key family of bacteria producing short-chain fatty acids (SCFAs), has been observed to be enriched in ICIs responders without severe irAEs (11). Previous studies have found that Faecalibacterium prausnitzii, a species belonging to the Ruminococcaceae family, was decreased in non-responders and those experiencing severe irAEs (11,17,45). These findings suggest a potential role of *Ruminococcaceae* as protective bacteria, possibly through the facilitation of SCFAs accumulation, in the mitigation of irAEs. Collinsella and Anaerostipes have limited evidence in irAEs, but the Collinsella genus has been reported to increase the production of IL-17A and enhance rheumatoid arthritis severity (56). In contrast, Anaerostipes, which belongs to Lachnospiraceae family, was conversely associated with the risk of high-grade irAEs in our study (11,18). These discrepancies observed in previous clinical studies might be attributed to several factors, including limited sample sizes in previous

observational studies, heterogeneity among the samples, and inadequate exploration of the taxonomic classification at the genus level of the gut microbiota. Therefore, a more detailed taxonomy for gut microbiota is crucial in dissecting the underlying mechanisms.

374

375

376

377

378

379

380

381 382

383

384

385

386 387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

Gut microbiota plays a pivotal role in modulating human immune homeostasis, and an imbalance in gut microbial composition, known as gut dysbiosis, has been implicated in several autoimmune diseases (15,16,57). IrAEs resemble autoimmune diseases in many aspects (38,58,59). Thus, despite the underlying mechanisms by which gut microbiota manipulates the development of irAEs remain poorly understood, we hypothesize that there might be some shared etiology of microbiota in autoimmune diseases and irAEs. These mechanisms include: (1) "Molecular mimicry": Evidence has shown that exposure to homologous amino acid sequences or epitopes of microbiota and aberrant activation of autoreactive B or T cells leads to multiple autoimmune diseases, such as multiple sclerosis (60), Guillain-Barré syndrome (61), Type 1 diabetes (62), Rheumatoid arthritis (63), and primary biliary cholangitis (64), which is referred to as "molecular mimicry" (65). It is believed that the systematic activation of the immune system during ICIs treatment triggers irAEs by bypassing self-tolerance in normal organs. One intriguing fact is that most irAEs occur in barrier organs (e.g., the intestinal tract, skin, and lungs) (58,66). This implies that the activated immune response might target the commensal microbiome as antigenic targets, although this hypothesis has not been fully demonstrated. (2) Decreased accumulation of SCFAs: SCFAs, including acetate, propionate, and butyrate, are a group of organic compounds primarily produced by the gut microbiota during the fermentation of dietary fibers. These metabolites were shown to improve the anti-cancer function of effector T cells, but they also seem to exhibit anti-inflammatory characteristics (67,68). Butyrate, one of the well-studied SCFAs, was shown to inhibit the activation of NF-κB and its downstream pathway (69), thereby reducing the production of pro-inflammatory cytokines such as IL-8 (70), while increasing the levels of anti-inflammatory factors like IL-10 (71). Moreover, SCFAs serve as a key energy source for colonocytes and maintain intestinal barrier integrity (72). Thus, the reduced abundance of SCFAs-producing bacteria along with its metabolites may participate in the development of irAEs. (3) Other mechanisms: Stimulation of the immune response by microbial-associated molecular patterns (e.g., include lipopolysaccharides (LPS), lipoproteins, flagellin and bacterial DNA) (73) and compromised vitamin B and polyamine metabolism that associated with gut dysbiosis (19) may also contribute to irAEs.

Taken together, the gut microbiota and the human immune system maintain a delicate balance under normal physiological conditions. Once the balance has been disturbed (e.g., ICIs treatment), the dysregulated microbiota might lead to the

development of undesirable irAEs. The primary management strategy for irAEs (> grade 2) involves the suspension of ICIs and/or utilizing immunosuppressive therapy (74). Nevertheless, one concern is that discontinuing ICIs or immunosuppressants may compromise treatment efficacy. Ideally, approaches to boost ICIs efficacy while reducing the accompanied irAEs are to be expected in the future. FMT, an approach to modulate gut microbiota, has been shown to increase ICIs efficacy in melanoma patients (75,76), and emerging evidence has demonstrated the mitigation of ICIs-related colitis through FMT in clinical practice (77). Interestingly, while irAEs and ICIs efficacy are often considered two sides of the same coin, certain gut bacteria, such as Akkermansia muciniphila and Faecalibacterium prausnitzii, have been shown to ameliorate irAEs and reinforce ICIs efficacy at the same time (78). This suggests that targeting gut microbiota could be an ideal approach to relieve irAEs symptoms and maintain ICIs efficacy, but further real-world evidence is needed to support this hypothesis.

Our study possesses several strengths. Firstly, we applied the MR approach to infer the causal associations between gut microbiota and irAEs, which effectively mitigates the influence of confounding factors and provides robust causal inference. Secondly, we conducted reverse MR analyses, confirming the absence of reverse causation, thereby enhancing the validity of our study. Thirdly, we applied MVMR in our analysis which further strengthened the validity and robustness of our study. Moreover, we incorporated several pleiotropy-robust methods such as MR PRESSO and cML-MA-BIC, further strengthening the robustness of our study. However, there are also certain inherent limitations in our study that should be considered when interpreting the findings. Firstly, our analysis is based on European-derived GWAS summary statistics, which might confine the generalization of the findings to other populations. Secondly, due to the utilization of summary statistics instead of raw data in the analysis, subgroup analyses based on ICIs regimes (e.g. PD-1/PD-L1 group, CTLA-4 group, and combined therapy group) could not be performed. Thirdly, the gut microbiota is shaped by multiple environmental factors, which confines the number of the identified significant gene loci in the GWAS (26). Thus, we relaxed the significant threshold of iVs to 1×10^{-5} (29) and employed Bonferroni correction to mitigate potential false positive results.

5. Conclusion

413 414

415

416417

418

419

420

421

422

423

424

425 426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443444

445

446

447

448

449

450

In conclusion, our univariable and multivariable MR analysis identified a strong causal association between *Lachnospiraceae* and irAEs, along with several other gut microbial taxa, such as *Akkermansia* and *Ruminiclostridium6* etc.. However, whether the FMT or probiotics could be used as interventional approaches to mitigate irAEs

- while reserving ICIs efficacy, additional randomized clinical trials (RCTs) are
- warranted. Furthermore, in-depth investigations are needed to elucidate the precise
- 453 mechanisms through which the gut microbiota influences the development of irAEs.

Declarations

454

455

458

459

466 467

472473

475

480 481

456 **Acknowledgment:**

We acknowledge all the investigators who have made their GWAS data available.

Author contributions

- 460 B. L. conceptualized this study. B. L., Z. L., and T. J. were involved in the analyses
- and manuscript drafting of this study. X. G. and X. Z. were involved in the data
- curation. B. L., T. J. X. Y., Z. C., and L. D. were involved in the interpretation of the
- methodology and results. B. L. and Z. L. were involved in the visualization of the
- 464 results. B. Z. was involved in obtaining funding and critical revision of the
- 465 manuscript.

Funding:

- 468 This study was supported by the National Nature Science Foundations of China
- 469 (Grant number 82203108), China Postdoctoral Science Foundation (Grant number
- 470 2022M722275), and the Key R&D Program of Sichuan Province, China (Grant
- 471 number 2023YFS0278).

Conflict of Interest:

474 All authors declare no conflict of interest.

476 **Data Availability:**

- This study was conducted using public-available data. The GWAS summary statistics
- 478 for gut microbiota are available at www.mibiogen.org, and GWAS summary statistics
- for irAEs are available at https://zenodo.org/record/6800429.

482 **Supplementary Information**

- Table S1. All Instrumental variables used for gut microbiota in the MR analysis.
- **Table S2.** Full results of primary MR analysis between bacterial taxa and all-grade
- 485 **irAEs**.
- 486 **Table S3.** Full results of primary MR analysis between bacterial taxa and high-grade
- 487 irAEs.

Table S4. Results of MR PRESS Global test.
 Table S5. Instrumental variables for irAEs in the reverse MR analysis.

- Table S6. Results of reverse MR analysis between all-grade irAEs and the identified
- 491 significant gut bacterial taxa.
- Table S7. Results of reverse MR analysis between high-grade irAEs and the identified
- 493 significant gut bacterial taxa.
- Table S8. Results of heterogeneity and horizontal pleiotropy analysis in reverse MR
- 495 analysis.
- Table S9. PhenoScanner results of instrumental variables used for significant bacterial
- 497 taxa in the MR analysis.
- Table S10. Description of datasets used for weight-associated anthropometric and
- 499 lifestyle factors in univariable MR analysis.
- Table S11. Multivariate MR estimates between gut microbiota (adjusted for BMI) and
- 501 irAEs.

502503

Table 1. Results of heterogeneity and horizontal pleiotropy analysis.

bacterial taxta (exposure)	irAEs (outcome)	Heterogeneity test			Horizontal pleiotropy results		
		Cochran's Q	df	p-value	Egger intercept	SE	p-value
Lachnospiraceae	High-grade irAEs	5.18	12	0.95	0.04	0.11	0.73
Verrucomicrobiaceae	High-grade irAEs	4.18	7	0.76	0.36	0.61	0.57
Eubacterium (fissicatena group)	High-grade irAEs	0.33	4	0.99	0.07	0.53	0.9
Akkermansia	High-grade irAEs	4.18	7	0.76	0.37	0.61	0.56
Anaerostipes	High-grade irAEs	4.13	6	0.66	0.38	0.2	0.11
Collinsella	High-grade irAEs	0.82	6	0.99	-0.19	0.23	0.43
Coprococcus3	High-grade irAEs	0.47	4	0.98	-0.28	0.46	0.59
Ruminiclostridium6	High-grade irAEs	3.54	7	0.83	-0.17	0.18	0.38
Lachnospiraceae	All-grade irAEs	17.3	12	0.14	0.09	0.11	0.43
Porphyromonadaceae	All-grade irAEs	0.66	4	0.96	0.05	0.28	0.87
Eubacterium (brachy group)	All-grade irAEs	1.41	5	0.92	-0.11	0.29	0.73
DefluviitaleaceaeUCG011	All-grade irAEs	0.48	4	0.98	-0.03	0.25	0.92
Peptococcus	All-grade irAEs	1.87	5	0.87	-0.12	0.24	0.66
Roseburia	All-grade irAEs	3.75	7	0.81	-0.31	0.22	0.21
RuminococcaceaeUCG004	All-grade irAEs	2.73	7	0.91	-0.23	0.3	0.47

df, degree of freedom; SE, standard error.

Table 2. Univariate MR estimates between common risk factors and irAEs.

		NSNP	Outcomes					
Exposures	Method		High-grade irAEs		All-grade irAEs			
			Beta (95%CI)	p-value	Beta (95%CI)	p-value		
Anthropometric factors								
BMI	IVW	314	-0.60 (-1.34, 0.14)	0.11	-0.74 (-1.41, -0.06)	0.03		
Waist circumference	IVW	26	0.61 (-1.01, 2.23)	0.46	0.05 (-1.15, 1.24)	0.94		
Waist circumference (adjusted for BMI)	IVW	46	0.00 (-1.37, 1.38)	1.00	-0.39 (-1.5, 0.73)	0.50		
Hip circumference	IVW	38	0.09 (-0.92, 1.10)	0.86	-0.63 (-1.7, 0.44)	0.25		
Hip circumference (adjusted for BMI)	IVW	52	0.65 (-0.38, 1.69)	0.21	0.47 (-0.52, 1.45)	0.35		
Waist-to-hip ratio	IVW	20	-0.28 (-2.21, 1.64)	0.77	-1.69 (-3.56, 0.18)	0.08		
Waist-to-hip ratio (adjusted for BMI)	IVW	25	0.84 (-0.88, 2.55)	0.34	-0.54 (-1.94, 0.85)	0.44		
Lifestyle factors								
Alcoholic drinks per week	IVW	14	-0.44 (-4.21, 3.33)	0.82	-0.06 (-3.24, 3.12)	0.97		
Cigarettes smoked per day	IVW	13	0.11 (-0.93, 1.16)	0.83	0.67 (-0.29, 1.63)	0.17		
Smoking initiation	IVW	54	0.08 (-1.21, 1.37)	0.90	-0.10 (-1.23, 1.04)	0.87		
Type 2 diabetes	IVW	79	-0.16 (-0.48, 0.17)	0.34	0.01 (-0.33, 0.34)	0.97		

BMI, body mass index; IVW, Inverse variance weighted method; NSNP, number of SNPs; irAEs, immune-related adverse events; 95%CI, 95% confidentical invterval.

510511512

	Outcomes						
Exposures in MVMR	High-grade irA	Es	All-grade irAEs				
	Beta (95%CI)	p-value	Beta (95%CI)	p-value			
Lachnospiraceae	-0.91 (-1.84, 0.01)	0.05	-1.07 (-1.96, -0.18)	0.02			
BMI	-0.43 (-1.2, 0.34)	0.28	0.01 (-0.33, 0.34)	0.34			

MVMR, multivariable MR analysis; BMI, body mass index; irAEs, immune-related adverse events; 95%CI, 95% confidentical invterval.

References:

513

514

- 1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.
- 516 Science. 2018 Mar 23;359(6382):1350–5.
- 517 2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
- Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J
- 519 Med. 2010 Aug 19;363(8):711–23.
- 520 3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al.
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.
- 522 **2015** Nov 5;373(19):1803–13.
- 4. Mj O, R M, Jl L, S L, Hj L, Ma M, et al. Nivolumab in patients with metastatic
- 524 DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer
- (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol [Internet].
- 526 2017 Sep [cited 2023 Feb 17];18(9). Available from:
- 527 https://pubmed.ncbi.nlm.nih.gov/28734759/
- 528 5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et
- al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N
- 530 Engl J Med. 2018 May 31;378(22):2078–92.
- 6. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat
- 532 Commun. 2020 Jul 30;11(1):3801.
- 7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et
- al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J
- 535 Med. 2015 May 21;372(21):2006–17.
- 8. Suresh K, Naidoo J. Lower Survival in Patients Who Develop Pneumonitis
- Following Immunotherapy for Lung Cancer. Clin Lung Cancer. 2020 May
- 538 1;21(3):e169–70.
- 539 9. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R,
- Rutkowski P, et al. Efficacy and Safety Outcomes in Patients With Advanced
- Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because
- of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin
- 543 Oncol Off J Am Soc Clin Oncol. 2017 Dec 1;35(34):3807–14.
- 10. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et
- al. Management of Immune-Related Adverse Events in Patients Treated With
- Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology
- 547 Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Jun
- 548 10;36(17):1714–68.
- 11. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al.
- 550 Diet-driven microbial ecology underpins associations between cancer immunotherapy
- outcomes and the gut microbiome. Nat Med. 2022 Nov;28(11):2344–52.
- 552 12. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, et al. Association of antibiotic
- 553 treatment with immune-related adverse events in patients with cancer receiving
- immunotherapy. J Immunother Cancer. 2022 Jan;10(1):e003779.
- 13. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al.

- Impact of antibiotic therapy on the development and response to treatment of immune
- checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019 Sep
- 558 5;7(1):242.
- 14. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al.
- Association of Antibiotic Exposure With Survival and Toxicity in Patients With
- Melanoma Receiving Immunotherapy. J Natl Cancer Inst. 2021 Feb 1;113(2):162–70.
- 562 15. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and
- Immune System Interactions. Microorganisms. 2020 Oct 15;8(10):1587.
- 16. Belkaid Y, Hand T. Role of the Microbiota in Immunity and inflammation. Cell.
- 565 2014 Mar 27;157(1):121–41.
- 566 17. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al.
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma
- patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol. 2017 Jun
- 569 1;28(6):1368–79.
- 570 18. McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al.
- 571 Intestinal microbiota signatures of clinical response and immune-related adverse
- events in melanoma patients treated with anti-PD-1. Nat Med. 2022
- 573 Mar;28(3):545–56.
- 574 19. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal
- 575 microbiome analyses identify melanoma patients at risk for
- checkpoint-blockade-induced colitis. Nat Commun. 2016 Feb 2;7:10391.
- 577 20. Bajinka O, Tan Y, Abdelhalim KA, Özdemir G, Qiu X. Extrinsic factors
- influencing gut microbes, the immediate consequences and restoring eubiosis. AMB
- 579 Express. 2020 Jul 25;10(1):130.
- 580 21. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet
- 581 Lond Engl. 1986 Mar 1;1(8479):507–8.
- 582 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
- studies: a guide, glossary, and checklist for clinicians. BMJ. 2018 Jul 12;362:k601.
- 584 23. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
- inference in epidemiological studies. Hum Mol Genet. 2014 Sep 15;23(R1):R89–98.
- 586 24. Chen L, Peters JE, Prins B, Persyn E, Traylor M, Surendran P, et al. Systematic
- Mendelian randomization using the human plasma proteome to discover potential
- therapeutic targets for stroke. Nat Commun. 2022 Oct 17;13:6143.
- 589 25. Zhang X, Theodoratou E, Li X, Farrington SM, Law PJ, Broderick P, et al.
- 590 Genetically predicted physical activity levels are associated with lower colorectal
- cancer risk: a Mendelian randomisation study. Br J Cancer. 2021 Mar;124(7):1330–8.
- 592 26. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J,
- 593 Demirkan A, et al. Large-scale association analyses identify host factors influencing
- human gut microbiome composition. Nat Genet. 2021 Feb;53(2):156–65.
- 595 27. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al.
- 596 Germline variants associated with toxicity to immune checkpoint blockade. Nat Med.
- 597 2022 Dec;28(12):2584–91.
- 598 28. Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization
- analyses support causal relationships between blood metabolites and the gut

- 600 microbiome. Nat Genet. 2022 Jan;54(1):52–61.
- 29. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al.
- 602 Causal relationships among the gut microbiome, short-chain fatty acids and metabolic
- 603 diseases. Nat Genet. 2019 Apr;51(4):600–5.
- 30. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent
- Developments in Mendelian Randomization Studies. Curr Epidemiol Rep.
- 606 2017;4(4):330–45.
- 31. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
- 608 Guidelines for performing Mendelian randomization investigations. Wellcome Open
- 609 Res. 2019;4:186.
- 610 32. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal
- pleiotropy in causal relationships inferred from Mendelian randomization between
- complex traits and diseases. Nat Genet. 2018 May;50(5):693–8.
- 613 33. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
- 614 instrumental variables in Mendelian randomization: comparison of allele score and
- summarized data methods. Stat Med. 2016 May 20;35(11):1880–906.
- 616 34. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- 617 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 618 Estimator. Genet Epidemiol. 2016 May;40(4):304–14.
- 619 35. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data
- 620 Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol.
- 621 2017 Dec 1;46(6):1985–98.
- 622 36. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian
- randomization robust to both correlated and uncorrelated pleiotropic effects. Am J
- 624 Hum Genet. 2021 Jul 1;108(7):1251–69.
- 625 37. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and
- 626 pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat
- 627 Med. 2021 Nov 10;40(25):5434–52.
- 628 38. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al.
- 629 Management of immune checkpoint blockade dysimmune toxicities: a collaborative
- 630 position paper. Ann Oncol Off J Eur Soc Med Oncol. 2016 Apr;27(4):559–74.
- 631 39. Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al. Risk of
- 632 irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors
- 633 for stage III or IV melanoma: results from a matched case–control study. Ann Rheum
- 634 Dis. 2022 Oct 1;81(10):1445–52.
- 40. Stanislawski MA, Dabelea D, Lange LA, Wagner BD, Lozupone CA. Gut
- microbiota phenotypes of obesity. NPJ Biofilms Microbiomes. 2019;5(1):18.
- 637 41. Deng K, Shuai M, Zhang Z, Jiang Z, Fu Y, Shen L, et al. Temporal relationship
- among adiposity, gut microbiota, and insulin resistance in a longitudinal human
- 639 cohort. BMC Med. 2022 May 19;20(1):171.
- 42. Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk Factors
- and Biomarkers for Immune-Related Adverse Events: A Practical Guide to
- 642 Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
- Front Immunol [Internet]. 2022 [cited 2023 Sep 12];13. Available from:

- 644 https://www.frontiersin.org/articles/10.3389/fimmu.2022.779691
- 43. Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at
- risk of immune-related diarrhea. Immunotherapy. 2019 Apr;11(5):385–96.
- 647 44. Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. Prospective correlation
- between the patient microbiome with response to and development of
- immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer.
- 650 2021 Jul 13;21(1):808.
- 45. Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, et al. Intestinal Microbiome
- 652 Associated With Immune-Related Adverse Events for Patients Treated With
- Anti-PD-1 Inhibitors, a Real-World Study. Front Immunol. 2021 Dec 16;12:756872.
- 46. Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut
- microbiome and immune-related adverse events in gastrointestinal cancer patients
- treated with immune checkpoint inhibitors. Front Cell Infect Microbiol [Internet].
- 657 2023 [cited 2023 Jun 18];13. Available from:
- https://www.frontiersin.org/articles/10.3389/fcimb.2023.1099063
- 659 47. Dou X, Gao N, Yan D, Shan A. Sodium Butyrate Alleviates Mouse Colitis by
- Regulating Gut Microbiota Dysbiosis. Anim Open Access J MDPI. 2020 Jul
- 661 7;10(7):1154.
- 48. Wu M, Li P, An Y, Ren J, Yan D, Cui J, et al. Phloretin ameliorates dextran
- sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota.
- 664 Pharmacol Res. 2019 Dec;150:104489.
- 49. Johanson DM, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A.
- Experimental autoimmune encephalomyelitis is associated with changes of the
- 667 microbiota composition in the gastrointestinal tract. Sci Rep. 2020 Sep
- 668 16;10(1):15183.
- 669 50. Ning J, Huang SY, Chen SD, Zhang YR, Huang YY, Yu JT. Investigating Casual
- 670 Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases:
- A Mendelian Randomization Study. J Alzheimers Dis JAD. 2022;87(1):211–22.
- 672 51. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut
- 673 microbiome influences efficacy of PD-1-based immunotherapy against epithelial
- 674 tumors. Science. 2018 Jan 5;359(6371):91–7.
- 52. Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, et al.
- 676 Cross-cohort gut microbiome associations with immune checkpoint inhibitor response
- in advanced melanoma. Nat Med. 2022 Mar;28(3):535–44.
- 53. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal
- Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with
- advanced non-small-cell lung cancer. Nat Med. 2022 Feb;28(2):315–24.
- 681 54. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL,
- et al. Fecal microbiota transplantation for refractory immune checkpoint
- inhibitor-associated colitis. Nat Med. 2018 Dec;24(12):1804–8.
- 684 55. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane
- 685 protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis
- associated tumourigenesis by modulation of CD8+ T cells in mice. Gut. 2020
- 687 Nov;69(11):1988–97.

- 56. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An
- expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.
- 690 Genome Med. 2016 Apr 21;8(1):43.
- 691 57. Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut
- 692 microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. 2023
- 693 Jan;23(1):9–23.
- 58. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse
- effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
- 696 Nat Rev Clin Oncol. 2019 Sep;16(9):563–80.
- 697 59. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events
- Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan
- 699 11;378(2):158–68.
- 700 60. Du C, Yao SY, Ljunggren-Rose Å, Sriram S. Chlamydia pneumoniae Infection of
- the Central Nervous System Worsens Experimental Allergic Encephalitis. J Exp Med.
- 702 2002 Dec 16;196(12):1639–44.
- 703 61. Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C,
- Monsalve DM, et al. Guillain–Barré syndrome, transverse myelitis and infectious
- 705 diseases. Cell Mol Immunol. 2018 Jun;15(6):547–62.
- 62. Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin
- 707 Immunol. 2015 Aug 1;159(2):143–53.
- 63. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al.
- Antibodies to citrullinated α -enolase peptide 1 are specific for rheumatoid arthritis
- and cross-react with bacterial enolase. Arthritis Rheum. 2008;58(10):3009–19.
- 711 64. Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary
- 712 cholangitis. Clin Exp Immunol. 2019 Jan 1;195(1):25–34.
- 713 65. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y,
- 714 Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018
- 715 Dec;95:100-23.
- 716 66. Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from
- checkpoint inhibitors. Trends Cancer. 2023 Jul 1;9(7):543–53.
- 718 67. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain
- fatty acids induce both effector and regulatory T cells by suppression of histone
- deacetylases and regulation of the mTOR–S6K pathway. Mucosal Immunol. 2015
- 721 **Jan**;8(1):80–93.
- 68. Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, et al. Microbial
- short-chain fatty acids modulate CD8+ T cell responses and improve adoptive
- immunotherapy for cancer. Nat Commun. 2021 Jul 1;12(1):4077.
- 725 69. Zhou G, Zhang N, Meng K, Pan F. Interaction between gut microbiota and
- immune checkpoint inhibitor-related colitis. Front Immunol. 2022 Oct
- 727 27;13:1001623.
- 728 70. BÖCKER U, NEBE T, HERWECK F, HOLT L, PANJA A, JOBIN C, et al.
- 729 Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. Clin Exp
- 730 Immunol. 2003 Jan;131(1):53–60.
- 71. Lee C, Kim BG, Kim JH, Chun J, Im JP, Kim JS. Sodium butyrate inhibits the

- NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental
- colitis in an IL-10 independent manner. Int Immunopharmacol. 2017 Oct;51:47–56.
- 73. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM.
- The role of short-chain fatty acids in the interplay between diet, gut microbiota, and
- 736 host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325–40.
- 737 73. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of
- checkpoint blockade-associated toxicity. J Exp Med. 2023 Mar 6;220(3):e20220948.
- 739 74. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al.
- 740 Management of Immune-Related Adverse Events in Patients Treated With Immune
- Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec
- 742 20;39(36):4073–126.
- 743 75. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison
- RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in
- melanoma patients. Science. 2021 Feb 5;371(6529):595–602.
- 746 76. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al.
- Fecal microbiota transplant promotes response in immunotherapy-refractory
- 748 melanoma patients. Science. 2021 Feb 5;371(6529):602–9.
- 749 77. Chen M, Liu M, Li C, Peng S, Li Y, Xu X, et al. Fecal Microbiota
- 750 Transplantation Effectively Cures a Patient With Severe Bleeding Immune
- 751 Checkpoint Inhibitor-Associated Colitis and a Short Review. Front Oncol. 2022 Jun
- 752 **10;12:913217**.

756

757

- 753 78. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al.
- 754 Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018
- 755 Nov 1;67(11):2056–67.

Figure legends:


- Figure 1. Overview of the study design.
- Initially, IVs were selected from the summary GWAS data of the gut microbiota and
- irAEs. Subsequently, by employing thresholds of p-value (IVW) < 0.05 and p-value
- (MR PRESSO) < 0.05, the identified gut microbiota that exhibited statistically
- significant associations were taken into further analysis. irAEs = immune-related
- adverse events; ICIs = immune checkpoint inhibitors; BMI = body mass index; WC =
- Waist circumference; HP = Hip circumference; WHR = Waist-to-hip ratio. (Created
- with BioRender.com).
- 766 **Figure 2.** Forest plots of MR results for the causal association between the identified
- eight gut microbial taxa and high-grade irAEs (grade 3 to 5 events). NSNP = number
- of SNPs; Beta = effect size from the exposure to the outcome; CI = confidence
- 769 interval.
- 770 **Figure 3.** Forest plots of MR results for the causal association between the identified
- 771 seven gut microbial taxa and all-grade irAEs (grade 1 to 5 events). NSNP = number of
- SNPs; Beta = effect size from the exposure to the outcome; CI = confidence interval.

773 Figure 4. Scatter plots of MR analysis between the gut microbial taxa and high-grade 774 irAEs (grade 3 to 5 events). 775 Figure 5. Scatter plots of MR analysis between the gut microbial taxa and all-grade 776 irAEs (grade 1 to 5 events). 777 Figure 6. Leave-one-out plots of MR analysis between the gut microbial taxa and 778 high-grade irAEs (grade 3 to 5 events). 779 Figure 7. Leave-one-out plots of MR analysis between the gut microbial taxa and 780 all-grade irAEs (grade 1 to 5 events). 781


Figure S1. Illustration of MR assumptions

782


783



High-grage irAEs



All-grade irAEs



-0.71 (-1.24,-0.18) **4.72E-02**

-0.71 (-1.59,0.16) 1.09E-01

-0.71 (-1.59,0.17) 1.15E-01

-0.84 (-1.95,0.26) 1.33E-01

-0.85 (-2.17,0.46) 2.60E-01

MR PRESSO -

cML-MA-BIC -

Weighted Median

Weighted Mode -

ML -


-2.0 -1.5 -1 -0.5 0 0.5

Beta


← risky protective →


High-grade irAEs

Family level




Verrucomicrobiaceae






Genus level

Ruminiclostridium6




Coprococcus3



SNP effect on genus.Coprococcus3


Anaerostipes




SNP effect on genus. Anaerostipes

Akkermansia


SNP effect on genus.Ruminiclostridium6



Collinsella




Eubacterium (fissicatena group)



All-grade irAEs

Family level

Lachnospiraceae




0.1


0.15

0.20


0.05

Porphyromonadaceae







Genus level




Ruminococcaceae UCG004




DefluviitaleaceaeUCG011









Peptococcus




High-grade irAEs


Family level








Genus level
















All-grade irAEs


Family level




Porphyromonadaceae




Genus level




Ruminococcaceae UCG 004



Defluviitaleaceaeucg011







Peptococcus

